• All News
• Consumer
• Pro
• New Drugs
• Pipeline
• Clinical Trials
• FDA Alerts

Therapeutic-Dose Anticoagulation Linked to Lower Mortality in COVID-19

By Elana Gotkine HealthDay Reporter

Medically reviewed by Carmen Pope, BPharm. Last updated on Dec 26, 2024.

THURSDAY, Dec. 26, 2024 -- For patients hospitalized for COVID-19, administration of therapeutic-dose versus prophylactic-dose anticoagulation with heparins is associated with lower 28-day mortality, according to a review published online Dec. 24 in the Annals of Internal Medicine.

Claire L. Vale, Ph.D., and colleagues from the World Health Organization Rapid Evidence Appraisal for COVID-19 Therapies Working Group, estimated the association of higher-dose versus lower-dose anticoagulation with clinical outcomes for patients hospitalized with COVID-19 using data from 20 eligible trials and two additional studies.

The researchers found that 28-day mortality was reduced with therapeutic-dose versus prophylactic-dose anticoagulation with heparins (odds ratio, 0.77; 95 percent confidence interval, 0.64 to 0.93; 11 trials included 6,297 patients, 5,456 of whom required low or no oxygen at randomization). For 28-day mortality, the odds ratios were 1.21 (95 percent confidence interval, 0.93 to 1.58) for therapeutic-dose versus intermediate-dose anticoagulation and 0.95 (95 percent confidence interval, 0.76 to 1.19) for intermediate- versus prophylactic-dose anticoagulation. Across predefined patient subgroups, treatment effects were broadly consistent; some analyses were limited in power. Fewer thromboembolic events were seen in association with higher- versus lower-dose anticoagulation, but the risk for major bleeding was greater.

"For each comparison, higher- compared with lower-dose anticoagulation was associated with fewer thromboembolic events but a greater risk for major bleeding," the authors write.

Abstract/Full Text (subscription or payment may be required)

Editorial (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Posted December 2024

More news resources

• FDA Medwatch Drug Alerts
• Daily MedNews
• News for Health Professionals
• New Drug Approvals
• New Drug Applications
• Drug Shortages
• Clinical Trial Results
• Generic Drug Approvals

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.